ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide
11 December 2019 - 10:30PM
ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru
Niagen® Pro 500, the largest daily serving of its patented
nicotinamide riboside (NR, or Niagen®) ingredient in the
world. The product will be available exclusively through
licensed healthcare practitioners in the United States, launching
this weekend at the American Academy for Anti-Aging Medicine (A4M)
Annual Meeting in Las Vegas, NV.
“This new product will allow practitioners to provide a unique
product to their patients who want more energy and improved
cellular health,” says ChromaDex CEO Rob Fried.
ChromaDex maintains a growing network of healthcare
practitioners who distribute Tru Niagen products to their patients
and is also partnered with Natural Partners Fullscript for
additional distribution.
“We are pleased to launch this new product exclusively through
the healthcare practitioner channel,” says ChromaDex Chief
Scientific Officer Dr. Matthew Roberts. “This new product launch
marks a major milestone in a year already characterized by several
new significant scientific publications, human clinical data, and
regulatory approvals around the world for ChromaDex.”
Niagen® is the only commercially available NR which has twice
been successfully reviewed under U.S. Food & Drug Association's
(FDA) new dietary ingredient (NDI) notification requirement and has
also been successfully notified to the FDA as generally recognized
as safe (GRAS). ChromaDex has also secured regulatory approvals on
its patent-protected ingredient in Canada, the European Union, and
Australia.
For additional information on the science supporting Tru Niagen,
please visit www.truniagen.com.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
chloride innovator and patent holder, ChromaDex. NIAGEN®
nicotinamide riboside chloride (NR), also supplied by ChromaDex, is
the sole active ingredient in TRU NIAGEN®. Multiple clinical trials
demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine
dinucleotide) levels, which decline with age. Only NIAGEN® has
twice been successfully reviewed under FDA's new dietary ingredient
(“NDI”) notification program, and has also been successfully
notified to the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside
chloride, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Vice President of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f993967a-6441-4840-a4c7-c0f714c01374
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024